Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
: To evaluate the value of the postvascular phase of contrast-enhanced ultrasound (CEUS) in differentiating between benign and metastatic lymph nodes (LNs) in patients with breast cancer (BC). : This study retrospectively analyzed 96 suspicious LNs in the lymphatic drainage area of the breast from 90 patients with BC. All LNs were assessed by conventional ultrasound (US) and CEUS following intravenous Sonazoid injection. All LNs underwent puncture biopsy, and pathological results were obtained. The correlations between US and CEUS indicators of LNs and LN metastasis (LNM) were analyzed. : Of the 96 LNs, 66 were metastatic. Overall, 80.00% (24/30) of the benign LNs exhibited relative hyper-enhancement in the postvascular phase, whereas 96.97% (64/66) of the metastatic LNs exhibited relative hypo-enhancement ( < 0.001). This CEUS finding was highly predictive of metastasis, with a sensitivity of 96.97%, specificity of 80.00%, positive predictive value of 91.43%, negative predictive value of 92.31%, and accuracy of 91.67%. The mean postvascular phase intensity (MPI) was significantly lower for malignant (median MPI, 12 dB) than for benign (median MPI, 75 dB) LNs. The postvascular phase was more sensitive, specific, and accurate than conventional US or the vascular phase of CEUS for the diagnosis of LNM, with an area under the curve of 0.95 (95% confidence interval: 0.89-0.99). : Qualitative and quantitative indicators of the postvascular phase of CEUS provide a reliable diagnostic approach to differentiate benign and metastatic LNs in patients with BC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11596673 | PMC |
| http://dx.doi.org/10.3390/medicina60111780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early differentiation of cervical lymphoma from benign lymphadenopathy remains challenging on conventional imaging. This study assesses the diagnostic efficacy of perfluorobutane contrast-enhanced ultrasound (CEUS) in differentiating early-stage cervical lymphoma from benign lymph nodes (LNs). From November 2023 to January 2025 we prospectively enrolled patients suspected of having cervical lymphoma based on ultrasound (US) findings and scheduled for LN biopsy.
View Article and Find Full Text PDFPerfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma.
Radiol Imaging Cancer
September 2025
Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan City, Hubei Province, China.
Purpose To evaluate the potential of perfluorobutane-enhanced US as a predictive biomarker for anti-programmed cell death (PD)-1 treatment response by targeting alternatively activated phenotype (M2)-polarized tumor-associated macrophages (TAMs) in hepatocellular carcinoma (HCC). Materials and Methods This study was conducted from June 2021 to February 2025. Male animal models included 4-week-old C57BL/6 mice for HCC models and 2-3-month-old New Zealand white rabbits for VX2 liver tumor models.
View Article and Find Full Text PDFPost-vascular phase of contrast-enhanced ultrasound with perfluorobutane for preoperative evaluation of axillary lymph node status in early-stage breast cancer.
Radiol Med
July 2025
Department of Ultrasound, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.
Purpose: To investigate the feasibility of post-vascular phase imaging on contrast-enhanced ultrasound (CEUS) with perfluorobutane for diagnosing axillary lymph node metastasis (ALNM) and prediction of metastatic burden in early-stage breast cancer.
Material And Methods: The prospective study enrolled patients with early-stage invasive breast cancer and non-palpable axillary lymph node (ALN) from November 2022 to June 2023. All participants of the entire cohort were scheduled for both conventional ultrasound (US) and CEUS with perfluorobutane examination immediately followed by US-guided core-needle biopsy basing on the guidance of CEUS result.
Improved diagnosis of small cervical lymph node metastasis using postvascular phase perfluorobutane CEUS in cancer patients.
BMC Cancer
January 2025
Department of Ultrasonography, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Background: Accurate identification of small metastatic lymph nodes (LNs) remains a significant challenge with conventional ultrasound (US) due to its limitations in sensitivity for smaller LNs. The use of contrast-enhanced ultrasound (CEUS), especially with perfluorobutane in the postvascular phase of CEUS, may improve the diagnosis of metastatic LNs in cancer patients. We sought to investigate the diagnostic accuracy of the postvascular phase of CEUS with perfluorobutane in identifying suspected small cervical LNs in cancer patients.
View Article and Find Full Text PDFUtilizing the Postvascular Phase of Contrast-Enhanced Ultrasound to Predict Breast Cancer Lymph Node Metastasis.
Medicina (Kaunas)
October 2024
Department of Ultrasound, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, China.
: To evaluate the value of the postvascular phase of contrast-enhanced ultrasound (CEUS) in differentiating between benign and metastatic lymph nodes (LNs) in patients with breast cancer (BC). : This study retrospectively analyzed 96 suspicious LNs in the lymphatic drainage area of the breast from 90 patients with BC. All LNs were assessed by conventional ultrasound (US) and CEUS following intravenous Sonazoid injection.
View Article and Find Full Text PDF